Objective To investigate the clinical efficacy of paclitaxel/cisplatin(TP)regimen combined with sintilimab in the treatment of advanced esophageal cancer and its impact on tumor markers.Methods A total of 120 patients with advanced esophageal cancer treated in our hospital from April 2020 to May 2023 were selected,and divided into two groups using random number table method,with 60 in each group.The patients in the control group were given TP regimen and those in the combined one neoadjuvant therapy with sintilimab on the basis of the treatment regimen in the control.The clinical efficacy,Karnofsky performance status(KPS),tumour markers and incidence of adverse reactions were compared between the 2 groups.Results The combined group reported a higher objective remission rate[51.6 7%(31/60)vs.33.33%(20/60),χ2=4.126,P<0.05]and disease control rate[88.33%(53/60)vs.63.33%(38/60),χ2=10.231,P<0.05]as compared with the control,showing statistical difference.After treatment,an increase in KAP scores was observed in the control group compared to baseline data[(82.97±6.21) scores vs.(71.41±6.01) scores]and the combined group[(89.61±5.28) scores vs.(71.88±6.72) scores],and combined group scored higher than the control,demonstrating statistical difference(P<0.05).Compared to baseline data,a reduction in squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA),and cytokeratin 19 fragment antigen 21-1(Cyfra21-1)was detected in the control group[(3.76±0.81) μg·L-1 vs.(2.19±0.37) μg·L-1,(41.32±5.01) ng·mL-1 vs.(26.87±3.21) ng·mL-1,(18.91±3.24) μg·L-1 vs.(8.62±1.16) μg·L-1]and the combined group[(3.59±0.76) μg·L-1 vs.(1.63±0.29) μg·L-1,(40.97±4.82) ng·mL-1 vs.(21.61±3.78) ng·mL-1,(18.24±2.95) μg·L-1 vs.(7.19±0.93) μg·L-1],and the reduction was more notable in the combined group than in the control,showing statistical difference(P<0.05).No statistical difference was found in overall adverse reaction rate between the 2 groups[51.67%(31/60)vs.48.33%(29/60),χ2=1.493,P=0.222].Conclusion TP regimen combined with Sintilimab is highly effective in treating invalids with advanced esophageal cancer since it can down-regulate the expression of tumour markers SCC,CEA,Cyfra21-1 in serum and improve functional status,and has a good safety profile.
NETL
NSTL
万方数据
